Hepatic fibrosis Clinical Trials

7 recruitingLast updated: July 25, 2026

There are 7 actively recruiting hepatic fibrosis clinical trials across 5 countries. Studies span Phase 2, Phase 3. Top locations include Atlanta, Georgia, United States, Barcelona, Spain, Bethesda, Maryland, United States. Updated daily from ClinicalTrials.gov.


Hepatic fibrosis Trials at a Glance

7 actively recruiting trials for hepatic fibrosis are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Atlanta, Barcelona, and Bethesda. Lead sponsors running hepatic fibrosis studies include Beijing Continent Pharmaceutical Co, Ltd., Children's Hospital of Philadelphia, and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.

Browse hepatic fibrosis trials by phase

Treatments under study

About Hepatic fibrosis Clinical Trials

Looking for clinical trials for Hepatic fibrosis? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatic fibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatic fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Natural History of Noncirrhotic Portal Hypertension

Cystic FibrosisTurner SyndromeImmunologic Deficiency Syndrome+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)400 enrolled1 locationNCT02417740
Recruiting

ARPKD Database Study

Autosomal Recessive Polycystic Kidney DiseaseNephronophthisisCongenital Hepatic Fibrosis+7 more
Children's Hospital of Philadelphia200 enrolled6 locationsNCT01401998
Recruiting

Screening for Advanced Liver Fibrosis Using Non-invasive Tests in Primary Care

Hepatic fibrosis
University Hospital, Grenoble500 enrolled1 locationNCT06119997
Recruiting
Phase 2

A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis

Chronic Hepatitis B With Hepatic Fibrosis
Beijing Continent Pharmaceutical Co, Ltd.200 enrolled1 locationNCT07364448
Recruiting
Phase 3

A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis

Chronic Hepatitis B With Hepatic Fibrosis
Beijing Continent Pharmaceutical Co, Ltd.300 enrolled1 locationNCT07343778
Recruiting
Phase 2

Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)

ObesityNAFLDFatty Liver+3 more
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau30 enrolled1 locationNCT06599918
Recruiting

Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University Hospital

Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University Hospital
Sohag University30 enrolled1 locationNCT06601829